Skip to content
value.today

Neuronetics, Inc.: peers

Change the peers

Neuronetics, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Neuronetics, Inc., MaxCyte, Inc., Exagen Inc., Anixa Biosciences, Inc., Biodesix, Inc., Insight Molecular Diagnostics Inc., Sera Prognostics, Inc., NRC Health side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureNeuronetics, Inc.base
STIM · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
MaxCyte, Inc.
MXCT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Exagen Inc.
XGN · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Anixa Biosciences, Inc.
ANIX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Biodesix, Inc.
BDSX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Insight Molecular Diagnostics Inc.
IMDX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Sera Prognostics, Inc.
SERA · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
NRC Health
NRC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$162 MOct 23, 2026 · Market data4th of 8$156 MOct 27, 2026 · Market data5th of 8$218 MOct 16, 2026 · Market data3rd of 8$117 MOct 29, 2026 · Market data6th of 8$265 MOct 23, 2026 · Market data2nd of 8$98 MOct 27, 2026 · Market data7th of 8$82 MOct 30, 2026 · Market data8th of 8$465 MOct 26, 2026 · Market data1st of 8$159 M8 ranked
Revenue (Better neither way: ranked highest first)$149 MFY2025 · SEC1st of 7$33 MFY2025 · SEC5th of 7$67 MFY2025 · SEC4th of 7——$89 MFY2025 · SEC3rd of 7$4 MFY2025 · SEC6th of 7$0 MFY2025 · SEC7th of 7$137 MFY2025 · SEC2nd of 7$67 M7 ranked
Net income (Higher is better)$-39 MFY2025 · SEC6th of 8$-45 MFY2025 · SEC7th of 8$-20 MFY2025 · SEC3rd of 8$-11 MFY2025 · SEC2nd of 8$-35 MFY2025 · SEC5th of 8$-50 MFY2025 · SEC8th of 8$-32 MFY2025 · SEC4th of 8$12 MFY2025 · SEC1st of 8$-34 M8 ranked
Employees (Better neither way: ranked highest first)——91December 31, 2025 · Profile3rd of 4220December 31, 2025 · Profile2nd of 4——————72December 31, 2025 · Profile4th of 4357December 31, 2025 · Profile1st of 41564 ranked
Growth
Market cap change, 30 days (Higher is better)-27.8%30 days to Oct 23, 2026 · Market data2nd of 2——+1.8%30 days to Oct 16, 2026 · Market data1st of 2——————————-13.0%2 ranked
Revenue growth (Higher is better)+99.2%FY2025 · SEC2nd of 691st96th-14.5%FY2025 · SEC6th of 612th8th+19.7%FY2025 · SEC4th of 667th78th————+24.1%FY2025 · SEC3rd of 673rd82nd+116.0%FY2025 · SEC1st of 693rd97th————-4.0%FY2025 · SEC5th of 618th19th+21.9%6 ranked
Revenue growth, 3 years a year (Higher is better)+31.8%FY2025 · SEC3rd of 682nd92nd-9.3%FY2025 · SEC6th of 612th11th+13.5%FY2025 · SEC4th of 661st77th————+32.3%FY2025 · SEC2nd of 683rd92nd+61.7%FY2025 · SEC1st of 692nd97th————-3.2%FY2025 · SEC5th of 619th23rd+22.6%6 ranked
Margins and returns
Gross margin (Higher is better)48.5%FY2025 · SEC4th of 434th61st81.1%FY2025 · SEC1st of 482nd92nd58.3%FY2025 · SEC2nd of 449th72nd————————56.6%FY2025 · SEC3rd of 448th70th————————57.5%4 ranked
Operating margin (Higher is better)-21.1%FY2025 · SEC2nd of 541st21st-157.1%FY2025 · SEC5th of 518th7th-21.1%FY2025 · SEC3rd of 540th21st————-31.5%FY2025 · SEC4th of 538th18th————————16.4%FY2025 · SEC1st of 584th80th-21.1%5 ranked
Net margin (Higher is better)-26.1%FY2025 · SEC2nd of 541st20th-135.1%FY2025 · SEC5th of 520th8th-30.0%FY2025 · SEC3rd of 538th18th————-39.8%FY2025 · SEC4th of 534th16th————————8.4%FY2025 · SEC1st of 576th71st-30.0%5 ranked
Free cash flow margin (Higher is better)-14.2%FY2025 · SEC2nd of 640th19th-109.5%FY2025 · SEC5th of 620th7th-21.4%FY2025 · SEC3rd of 636th16th————-26.6%FY2025 · SEC4th of 634th15th-624.6%FY2025 · SEC6th of 64th1st————11.5%FY2025 · SEC1st of 675th73rd-24.0%6 ranked
Return on equity (Higher is better)-155.7%FY2025 · SEC6th of 615th7th-23.6%FY2025 · SEC2nd of 659th26th-147.8%FY2025 · SEC5th of 616th7th-62.2%FY2025 · SEC4th of 637th16th————————-51.8%FY2025 · SEC3rd of 642nd18th51.3%FY2025 · SEC1st of 697th96th-57.0%6 ranked
Return on invested capital (Higher is better)————————————————————————————17.3%FY2025 · SEConly one with it72nd72nd17.3%—
Valuation
P/E ratio (Better neither way: ranked highest first)————————————————————————————72.3×price Oct 26, 2026 · Market dataonly one with it82nd92nd72.3×—
Price to sales (Better neither way: ranked highest first)1.0×price Oct 23, 2026 · Market data6th of 617th29th4.5×price Oct 27, 2026 · Market data2nd of 655th74th3.0×price Oct 16, 2026 · Market data4th of 644th61st————2.5×price Oct 23, 2026 · Market data5th of 639th55th24.2×price Oct 27, 2026 · Market data1st of 685th95th————3.2×price Oct 26, 2026 · Market data3rd of 645th63rd3.1×6 ranked
Price to book (Better neither way: ranked highest first)7.2×price Oct 23, 2026 · Market data4th of 678th84th0.9×price Oct 27, 2026 · Market data6th of 617th18th12.5×price Oct 16, 2026 · Market data2nd of 687th92nd7.7×price Oct 29, 2026 · Market data3rd of 679th85th————————1.1×price Oct 30, 2026 · Market data5th of 620th23rd33.3×price Oct 26, 2026 · Market data1st of 695th97th7.5×6 ranked
Free cash flow yield (Higher is better)-13.1%price Oct 23, 2026 · Market data5th of 839th18th-23.2%price Oct 27, 2026 · Market data6th of 830th13th-6.5%price Oct 16, 2026 · Market data3rd of 850th25th-5.3%price Oct 29, 2026 · Market data2nd of 854th27th-8.9%price Oct 23, 2026 · Market data4th of 845th22nd-25.8%price Oct 27, 2026 · Market data7th of 828th13th-32.2%price Oct 30, 2026 · Market data8th of 826th11th3.4%price Oct 26, 2026 · Market data1st of 880th56th-11.0%8 ranked
Financial strength
Debt to equity (Lower is better)2.9×FY2025 · SEC2nd of 392nd90th————1.3×FY2025 · SEC1st of 381st76th————————————————5.4×FY2025 · SEC3rd of 395th95th2.9×3 ranked
Net debt to EBITDA (Lower is better)————————————————————————————2.4×FY2025 · SEConly one with it59th54th2.4×—
Interest cover (Higher is better)-4.1×FY2025 · SEC2nd of 258th33rd————————————-3.6×FY2025 · SEC1st of 260th34th————————————-3.9×2 ranked
Piotroski F-score (Higher is better)4 of 9FY2025 · SEC1st of 2——3 of 9FY2025 · SEC2nd of 2——————————3.5 of 92 ranked
Scorecard
Scorecard (Higher is better)7 of 22FY2025 · Scorecard4th of 83 of 20FY2025 · Scorecard7th of 88 of 22FY2025 · Scorecard3rd of 82 of 12FY2025 · Scorecard6th of 88 of 20FY2025 · Scorecard2nd of 85 of 17FY2025 · Scorecard5th of 82 of 14FY2025 · Scorecard8th of 813 of 29FY2025 · Scorecard1st of 831% passed8 ranked
Valuation checks (Higher is better)1 of 5FY2025 · Scorecard2nd of 81 of 5FY2025 · Scorecard2nd of 81 of 5FY2025 · Scorecard2nd of 80 of 4FY2025 · Scorecard7th of 81 of 5FY2025 · Scorecard2nd of 80 of 5FY2025 · Scorecard7th of 81 of 4FY2025 · Scorecard1st of 81 of 6FY2025 · Scorecard6th of 820% passed8 ranked
Growth checks (Higher is better)4 of 6FY2025 · Scorecard2nd of 80 of 6FY2025 · Scorecard6th of 84 of 6FY2025 · Scorecard2nd of 80 of 2FY2025 · Scorecard6th of 85 of 6FY2025 · Scorecard1st of 84 of 6FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard6th of 81 of 6FY2025 · Scorecard5th of 842% passed8 ranked
Profitability checks (Higher is better)1 of 5FY2025 · Scorecard3rd of 80 of 5FY2025 · Scorecard5th of 81 of 5FY2025 · Scorecard3rd of 80 of 3FY2025 · Scorecard5th of 81 of 4FY2025 · Scorecard2nd of 80 of 2FY2025 · Scorecard5th of 80 of 3FY2025 · Scorecard5th of 85 of 6FY2025 · Scorecard1st of 810% passed8 ranked
Financial health checks (Higher is better)1 of 5FY2025 · Scorecard8th of 81 of 3FY2025 · Scorecard4th of 82 of 5FY2025 · Scorecard3rd of 81 of 2FY2025 · Scorecard2nd of 81 of 4FY2025 · Scorecard7th of 81 of 3FY2025 · Scorecard4th of 81 of 3FY2025 · Scorecard4th of 83 of 5FY2025 · Scorecard1st of 833% passed8 ranked
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecard4th of 81 of 1FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard4th of 81 of 1FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard4th of 80 of 1FY2025 · Scorecard4th of 80 of 1FY2025 · Scorecard4th of 83 of 6FY2025 · Scorecard3rd of 80% passed8 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)57.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 862.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 840.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 818.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 841.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 856.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 849.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 851.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 850.1%8 ranked
Institutions holding (Better neither way: ranked highest first)962026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 81192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8782026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8752026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8602026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8442026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8482026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 81262026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8778 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)-11.3 pp2026-Q2 against 2026-Q1 · 13F7th of 7+0.3 pp2026-Q2 against 2026-Q1 · 13F4th of 7-6.1 pp2026-Q2 against 2026-Q1 · 13F6th of 7+0.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 7+2.2 pp2026-Q2 against 2026-Q1 · 13F1st of 7-2.5 pp2026-Q2 against 2026-Q1 · 13F5th of 7——+0.5 pp2026-Q2 against 2026-Q1 · 13F3rd of 7+0.3 pp7 ranked
Dividends
Dividend yield (Higher is better)————————————————————————————2.4%FY2025 · SEConly one with it82nd55th2.4%—
Shareholder yield (Higher is better)————————————————————————————6.7%FY2025 · SEConly one with it82nd78th6.7%—
Dividend payout (Better neither way: ranked highest first)————————————————————————————94.7%FY2025 · SEConly one with it92nd82nd94.7%—
Dividend per share (Better neither way: ranked highest first)——————————————$0.52FY2025 · SEConly one with it$0.52—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Neuronetics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; MaxCyte, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Exagen Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Anixa Biosciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Biodesix, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Insight Molecular Diagnostics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Sera Prognostics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NRC Health: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Neuronetics, Inc.-21.1%FY2025
41st percentile in Healthcaremedian -7.8%, 678 companies
21st percentile in USAmedian 3.4%, 2,607 companies
MaxCyte, Inc.-157.1%FY2025
18th percentile in Healthcaremedian -7.8%, 678 companies
7th percentile in USAmedian 3.4%, 2,607 companies
Exagen Inc.-21.1%FY2025
40th percentile in Healthcaremedian -7.8%, 678 companies
21st percentile in USAmedian 3.4%, 2,607 companies
Anixa Biosciences, Inc.———
Biodesix, Inc.-31.5%FY2025
38th percentile in Healthcaremedian -7.8%, 678 companies
18th percentile in USAmedian 3.4%, 2,607 companies
Insight Molecular Diagnostics Inc.———
Sera Prognostics, Inc.———
NRC Health16.4%FY2025
84th percentile in Healthcaremedian -7.8%, 678 companies
80th percentile in USAmedian 3.4%, 2,607 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$38 M$76 M$114 M$152 M20102012201420162018202020222024Neuronetics, Inc. $149 MMaxCyte, Inc. $33 MExagen Inc. $67 MAnixa Biosciences, Inc. $0 MBiodesix, Inc. $89 MInsight Molecular Diagnostics Inc. $4 MSera Prognostics, Inc. $0 MNRC Health $137 M

Rank in the group

1st2nd3rd4th5th6th7th8th201120122013201420152016201720182019202020212022202320242025Neuronetics, Inc.: 2nd of 3 in 2016Neuronetics, Inc.: 2nd of 3 in 2017Neuronetics, Inc.: 2nd of 4 in 2018Neuronetics, Inc.: 2nd of 6 in 2019Neuronetics, Inc.: 2nd of 7 in 2020Neuronetics, Inc.: 2nd of 8 in 2021Neuronetics, Inc.: 2nd of 7 in 2022Neuronetics, Inc.: 2nd of 8 in 2023Neuronetics, Inc.: 2nd of 8 in 2024Neuronetics, Inc.: 1st of 7 in 2025Neuronetics, Inc.MaxCyte, Inc.: 5th of 6 in 2019MaxCyte, Inc.: 5th of 7 in 2020MaxCyte, Inc.: 5th of 8 in 2021MaxCyte, Inc.: 4th of 7 in 2022MaxCyte, Inc.: 5th of 8 in 2023MaxCyte, Inc.: 5th of 8 in 2024MaxCyte, Inc.: 5th of 7 in 2025MaxCyte, Inc.Exagen Inc.: 3rd of 4 in 2018Exagen Inc.: 3rd of 6 in 2019Exagen Inc.: 4th of 7 in 2020Exagen Inc.: 4th of 8 in 2021Exagen Inc.: 3rd of 7 in 2022Exagen Inc.: 3rd of 8 in 2023Exagen Inc.: 4th of 8 in 2024Exagen Inc.: 4th of 7 in 2025Exagen Inc.Anixa Biosciences, Inc.: 2nd of 2 in 2011Anixa Biosciences, Inc.: 2nd of 2 in 2012Anixa Biosciences, Inc.: 2nd of 2 in 2013Anixa Biosciences, Inc.: 2nd of 2 in 2014Anixa Biosciences, Inc.: 2nd of 2 in 2015Anixa Biosciences, Inc.: 3rd of 3 in 2016Anixa Biosciences, Inc.: 3rd of 3 in 2017Anixa Biosciences, Inc.: 4th of 4 in 2018Anixa Biosciences, Inc.: 6th of 6 in 2019Anixa Biosciences, Inc.: 7th of 8 in 2021Anixa Biosciences, Inc.: 8th of 8 in 2023Anixa Biosciences, Inc.: 7th of 8 in 2024Anixa Biosciences, Inc.Biodesix, Inc.: 4th of 6 in 2019Biodesix, Inc.: 3rd of 7 in 2020Biodesix, Inc.: 3rd of 8 in 2021Biodesix, Inc.: 5th of 7 in 2022Biodesix, Inc.: 4th of 8 in 2023Biodesix, Inc.: 3rd of 8 in 2024Biodesix, Inc.: 3rd of 7 in 2025Biodesix, Inc.Insight Molecular Diagnostics Inc.: 6th of 7 in 2020Insight Molecular Diagnostics Inc.: 6th of 8 in 2021Insight Molecular Diagnostics Inc.: 6th of 7 in 2022Insight Molecular Diagnostics Inc.: 6th of 8 in 2023Insight Molecular Diagnostics Inc.: 6th of 8 in 2024Insight Molecular Diagnostics Inc.: 6th of 7 in 2025Insight Molecular DiagnostSera Prognostics, Inc.: 7th of 7 in 2020Sera Prognostics, Inc.: 8th of 8 in 2021Sera Prognostics, Inc.: 7th of 7 in 2022Sera Prognostics, Inc.: 7th of 8 in 2023Sera Prognostics, Inc.: 8th of 8 in 2024Sera Prognostics, Inc.: 7th of 7 in 2025Sera Prognostics, Inc.NRC Health: 1st of 2 in 2011NRC Health: 1st of 2 in 2012NRC Health: 1st of 2 in 2013NRC Health: 1st of 2 in 2014NRC Health: 1st of 2 in 2015NRC Health: 1st of 3 in 2016NRC Health: 1st of 3 in 2017NRC Health: 1st of 4 in 2018NRC Health: 1st of 6 in 2019NRC Health: 1st of 7 in 2020NRC Health: 1st of 8 in 2021NRC Health: 1st of 7 in 2022NRC Health: 1st of 8 in 2023NRC Health: 1st of 8 in 2024NRC Health: 2nd of 7 in 2025NRC Health
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearNeuronetics, Inc.MaxCyte, Inc.Exagen Inc.Anixa Biosciences, Inc.Biodesix, Inc.Insight Molecular Diagnostics Inc.Sera Prognostics, Inc.NRC Health
2025$149 MSEC1st$33 MSEC5th$67 MSEC4th—$89 MSEC3rd$4 MSEC6th$0 MSEC7th$137 MSEC2nd
2024$75 MSEC2nd$39 MSEC5th$56 MSEC4th$0 MSEC7th$71 MSEC3rd$2 MSEC6th$0 MSEC8th$143 MSEC1st
2023$71 MSEC2nd$41 MSEC5th$53 MSEC3rd$0 MSEC8th$49 MSEC4th$2 MSEC6th$0 MSEC7th$149 MSEC1st
2022$65 MSEC2nd$44 MSEC4th$46 MSEC3rd—$38 MSEC5th$1 MSEC6th$0 MSEC7th$152 MSEC1st
2021$55 MSEC2nd$34 MSEC5th$48 MSEC4th$1 MSEC7th$55 MSEC3rd$2 MSEC6th$0 MSEC8th$148 MSEC1st
2020$49 MSEC2nd$26 MSEC5th$42 MSEC4th—$46 MSEC3rd$1 MSEC6th$0 MSEC7th$133 MSEC1st
2019$63 MSEC2nd$22 MSEC5th$40 MSEC3rd$0 MSEC6th$25 MSEC4th——$128 MSEC1st
2018$53 MSEC2nd—$32 MSEC3rd$1 MSEC4th———$120 MSEC1st
2017$40 MSEC2nd——$0 MSEC3rd———$118 MSEC1st
2016$34 MSEC2nd——$0 MSEC3rd———$109 MSEC1st
2015———$9 MSEC2nd———$102 MSEC1st
2014———$4 MSEC2nd———$99 MSEC1st

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Neuronetics, Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • MaxCyte, Inc.MXCT · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $156 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $156 M (Oct 27, 2026) · revenue $33 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Exagen Inc.XGN · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $218 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $218 M (Oct 16, 2026) · revenue $67 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Anixa Biosciences, Inc.ANIX · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $117 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $117 M (Oct 29, 2026)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Biodesix, Inc.BDSX · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $265 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $265 M (Oct 23, 2026) · revenue $89 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Insight Molecular Diagnostics Inc.IMDX · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $98 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $98 M (Oct 27, 2026) · revenue $4 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Sera Prognostics, Inc.SERA · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $82 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $82 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • NRC HealthNRC · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $465 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $465 M (Oct 26, 2026) · revenue $137 M (year to December 2025)
    93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)
    In the group
  • IB Acquisition Corp.IBAC · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $55 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $55 M (Sep 28, 2026)
    93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)
    + Add
  • Standard BioTools Inc.FLDM · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $243 M market cap against $162 M · Same country: USA
    Market cap $243 M (last known, Jan 7, 2022) · revenue $138 M (year to December 2020)
    92 of 100 (industry or sector 50 + size 27 + country 15)
    + Add
  • Myriad Genetics, Inc.MYGN · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $531 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $531 M (Oct 21, 2026) · revenue $825 M (year to December 2025)
    92 of 100 (industry or sector 50 + size 22 + country 15 + figures on file 5)
    + Add
  • Fulgent Genetics, Inc.FLGT · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $582 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $582 M (Oct 9, 2026) · revenue $323 M (year to December 2025)
    92 of 100 (industry or sector 50 + size 22 + country 15 + figures on file 5)
    + Add
  • DarioHealth Corp.DRIO · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $42 M market cap against $162 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $42 M (Oct 22, 2026) · revenue $22 M (year to December 2025)
    91 of 100 (industry or sector 50 + size 21 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.